Shots:

• The P-III OA study involves assessing of tanezumab (2.5mg/5mg- SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across EU and Japan for 24 wks.
• The study showed a meeting in all 1EPs improvement in pain- physical function with well-tolerated results and has shown the ratio of RPOA type 1 to RPOA type 2 (2:1)
• Tanezumab is a mAb inhibiting nerve growth factor (NGF) and has received FDA’s Fast Track designation for OA pain and CLBP. In 2013- Pfizer and Lilly globally collaborated to jointly develop and commercialize tanezumab

Ref: Business Wire | Image: Telegraph India